Depression is the leading global cause of disability, affecting about 300 million people worldwide.1,2 Depending on the number and severity of symptoms, depressive episodes can be classified as mild, moderate, and severe. Previous studies have typically focused on the treatment of severe refractory depression, while there have been few studies on the treatment of mild-to-moderate depression. However, patients with mild-to-moderate depression may develop severe episodes if not properly treated. Antidepressant dietary supplements have been suggested as an alternative treatment for depression, but the effectiveness of these supplements varies widely, and their efficacy has not been rigorously tested in clinical trials. NeuroWell contains all plant extracted ingredients and affects multiple pathways to provide a multi-targeted treatment. Preliminary results indicated that NeuroWell is safe and meets the U.S. FDA standards for dietary supplements. NeuroWell is currently in the U.S. market to relieve depression and anxiety and has exhibited remarkable clinical effects. However, no systematic clinical trials have been performed to investigate the effects of NeuroWell on mild-to-moderate depression and anxiety. Deanxit is an antidepressant widely used in the treatment of depression. It is a mixture of flupentixol and melitracine, which increases the concentration of neurotransmitters in the intracerebral synaptic space. It is mainly used in patients with mild-to-moderate anxiety and depression with major somatization symptoms.3, 4, 5 Thus, Deanxit was selected as the positive control for NeuroWell in this clinical trial.